Navigation Links
Pebbles Along the 'Path' to Personalized Medicine
Date:6/22/2010

Panel discussion with Georgetown experts to address biotechnology, science, policy and ethical issues

WASHINGTON, June 22 /PRNewswire-USNewswire/ -- Earlier this week, the National Institutes of Health and the Food and Drug Administration outlined a "path" to accelerate and help ensure the safety of personalized medicine -- treatments tailored to match a person's genetic make-up.  Significant progress in this rapidly developing field will hinge on biotechnology and will be impacted by the law, healthcare policy and ethical issues.

On Wednesday, June 23rd, Georgetown University Medical Center will explore the many issues of personalized medicine with a special panel featuring experts from healthcare, bioethics, policy and law.

Panelists for the event include:

  • Howard J. Federoff, MD, PhD, executive vice president for health sciences; executive dean of Georgetown University School of Medicine
  • Kevin T. Fitzgerald, SJ, PhD, research associate professor in the Department of Oncology; Dr. David P. Lauler Chair in Catholic Health Care Ethics
  • Lawrence O. Gostin'/>"/>

SOURCE Georgetown University Medical Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
4. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
7. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso
10. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
11. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Lexington,Kentucky and Queens, New York (PRWEB) October 02, ... is pleased to announce funding received to ... pathway in Alzheimer’s disease. A grant award from ... Institute on Aging (NIA), National Institutes of Health ... as Novel AD Therapeutics." The company also received ...
(Date:10/2/2014)... (PRWEB) October 02, 2014 Permian Plastics, ... in the St. Louis, Missouri, area on October 24th, ... become a leading plastic injection molder in the Midwest. ... and is a supplier to many Fortune 500 clients. ... support every step of the way, from concept to ...
(Date:10/2/2014)... 2014 At a time when many are ... has introduced a new kind of squeeze aimed at containing ... Scienceware® Squeeze Rite™ Wash Bottle , catalog no. F11717-0030. ... the bottle reduces the waste of reagents, solutions and other ... , “Easier to squeeze when compared to standard 500ml bottles, ...
(Date:10/2/2014)... 2014  NKT Therapeutics today announced that the ... Track designation to NKTT120, the company,s lead therapeutic ... disease.  NKTT120 is a humanized monoclonal antibody that ... that has been demonstrated to be a key ... sickle cell disease.  Fast Track designation is intended ...
Breaking Biology Technology:Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 3Permian Plastics LLC Celebrates 20 Years As Leading Manufacturer of Plastic Molds 2New Wash Bottle Reduces Waste of Reagents, Solutions, and Other Liquids 2FDA Grants Fast Track Designation to NKT Therapeutics' NKTT120 for the Treatment of Sickle Cell Disease 2
... PARK, N.Y., Feb. 6 MINRAD International,Inc. (Amex: ... Company received a notice from,NYSE Alternext US LLC (the ... stock of the Company from the Exchange by filing ... to Section,1009(d) of the NYSE Alternext US Company Guide. ...
... Sky One Medical,Inc. ("China Sky One Medical" or ... leading,fully integrated pharmaceutical company producing over-the-counter drugs in,the ... the Company,s,Chief Financial Officer, Mr. Yu-bo (Stanley) Hao, ... Roth 21st Annual OC Growth Stock,Conference in Dana ...
... BIRMINGHAM, Ala., Feb. 6 BioCryst Pharmaceuticals, Inc. (Nasdaq: ... the fourth quarter and year ended December 31, 2008. ... months ended December 31, 2008, the Company reported collaborative ... compared to $28.2 million for the three months ended ...
Cached Biology Technology:MINRAD Receives Notice That NYSE Alternext Intends to File Delisting Application With Securities and Exchange Commission 2MINRAD Receives Notice That NYSE Alternext Intends to File Delisting Application With Securities and Exchange Commission 3China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 2BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 3BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 4BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 5BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 6BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 7BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 8BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 9
(Date:9/30/2014)... to using marijuana, new research, involving mice and published ... Journal of Leukocyte Biology , suggests that just ... should. That,s because a team of Italian scientists have ... long-term damage to the immune system. This damage may ... as multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra Automation, ... for the biotech and power generation industries, ... RECONN Bioprocess Manager, an easy-to-use and cost-effective ... towards bioprocess development laboratories. ... bioreactor and analyzer systems. Accessing and consolidating ...
(Date:9/29/2014)... study confirms that the exposure to tar tended to ... regular cigarettes. Similarly, exposure to nicotine tended to ... type of cigarette in several countries around the world. ... toxic chemicals in the smoke of these cigarettes are ... levels of chemicals in the smoke are not necessarily ...
Breaking Biology News(10 mins):Adolescent exposure to thc may cause immune systems to go up in smoke 2Spectra Automation Introduces RECONN Bioprocess Manager 2Slim cigarette smokers not exposed to more harmful chemicals 2
... a group of human subjects to operate a robot-controlled joystick, ... "learns" to control certain muscle movements, the more likely it ... results, the investigators say, could alter rehabilitation approaches for people ... , In a report on the work in the ...
... and exercise performance measures of trained cyclists at high ... a lot -- up to 45% -- while others ... level. , Ten cyclists who took sildenafil at altitude ... kilometers by 15% compared to placebo trials at altitude. ...
... for breast cancer do not increase their life expectancy ... analysis by researchers from UC Davis, UCSF, the University ... addition, the researchers showed that tamoxifen is an extraordinarily ... per year of life saved. The study will be ...
Cached Biology News:New approach to vaccine development provides potent, long-lasting immunity 2New approach to vaccine development provides potent, long-lasting immunity 3Viagra improves high altitude exercise performance up to 45% for some 2Viagra improves high altitude exercise performance up to 45% for some 3Viagra improves high altitude exercise performance up to 45% for some 4Tamoxifen for breast cancer prevention does not benefit most women 2Tamoxifen for breast cancer prevention does not benefit most women 3
... series of refrigerated cold traps offers a ... low volatility/aqueous solvents or high volatility solvents. ... vacuum concentrators/centrifugal evaporators. Also used for maintaining ... as used in electron microscopes. Can be ...
... Refrigerated Vapor Trap is specifically designed ... solvents such as DMSO and DMF ... constant temperature refrigeration system set at ... conditions for DMSO, while completely eliminating ...
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
Thermo Forma provides an array of accessory Racks for the Cryo/CryoPlus 16" Diameter storage system. To maximise inventory capacity a Jumbo Arrowhead configuration is recommended. You may choose betw...
Biology Products: